Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Enhancement of Methylphenidate Treatment by Psychosocial Intervention and Support

12 mars 2014 uppdaterad av: Manfred Doepfner, University of Cologne

Enhancement of Psychosocial Functioning, Quality of Life, Satisfaction With Medication and Medication Compliance of Methylphenidate Treatment by Psychosocial Intervention and Support

The main purpose of this study is to evaluate the effectiveness of a parenting enhancement training (PET) for parents with children diagnosed with Attention Deficit-/Hyperactivity Disorder (ADHD) who are already medicated with methylphenidate.

Studieöversikt

Status

Okänd

Betingelser

Intervention / Behandling

Detaljerad beskrivning

The main purpose of this study is to evaluate the effectiveness of a parenting enhancement training (PET) for parents with children diagnosed with Attention Deficit-/Hyperactivity Disorder (ADHD) already medicated with methylphenidate (MPH). This particular PET was developed at the Department of Child and Adolescent Psychiatry and Psychotherapy at the University of Cologne and has already been evaluated in several studies. MPH treatment has been proven to be efficacious in the reduction of ADHD symptoms. However, despite optimal titration a substantial percentage of children still suffer from residual symptoms and impairment in psychosocial functioning. Therefore, there is still room for improvement in satisfaction with medication. Moreover, a substantial rate of patients with good treatment effects fails to comply with medication during the course of treatment. This parenting enhancement training (PET) mainly conducted via written materials and telephone support will be introduced in patients already treated with MPH. Effects are expected on symptoms of ADHD as well as on comorbid oppositional symptoms. Further outcome parameters are satisfaction with medication and medication compliance of MPH treatment, psychosocial functioning as well as parenting skills. Parenting skills are a main focus of the PET and ADHD symptoms shall be improved through improving parenting skills. Besides focusing on symptoms, recent research often focuses on improvement of quality of life and impairment in psychosocial functioning (e. g. family, school, leisure time) as well. Not only suffer patients from the main symptoms. Many patients suffer as well from the symptoms' consequences, which is often an overall impairment. Satisfaction with medication and medication compliance are fundamental conditions for the success of a long term medical therapy. However, many studies show a lack of compliance.

Studietyp

Interventionell

Inskrivning (Förväntat)

100

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

  • Tyskland
    • NRW
      • Cologne, NRW, Tyskland, 50937
        • Department of Child and Adolescent Psychiatry and Psychotherapy at the University of Cologne

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

6 år till 12 år (Barn)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • The child attends school and is aged 6 to 12
  • Primary diagnosis of ADHD
  • Medication with methylphenidate in stable doses for at least two months
  • Currently, no change of medication is planned
  • The parents are motivated to participate in the parenting enhancement training
  • The parents have a command of written and spoken German
  • Psychosocial impairment measured with WFIRS-P

Exclusion criteria:

- the family takes presumably part in psychotherapy with an intensive parenting training component during the duration of the intervention

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Inget ingripande: treatment as usual with MPH
In the first twelve months of intervention the children receive treatment as usual with MPH and do not get any further intervention. Afterwards, the families get the opportunity to take part in the program which is then conducted for a duration of four months. Measurements are performed at the beginning of the program, after six moths, after 12 months and additionally after 16 months.
Aktiv komparator: Psychosocial intervention
Parenting Enhancement Training as a form of psychosocial intervention is a guided program. Parents get the opportunity to discuss written information with a therapist in 20 minutes telephone calls. 14 telephone calls are offered. The whole intervention lasts for a period of one year. Booklets are mailed via post within the first 4 months. First 9 telephone calls are also within the first 4 months, usually every two weeks. Telephone calls 10 and 11 are within 5th or 6th month, telephone calls 12 to 14 are within 7th to 12th month with a two monthly time period in between.
Beteende: Enhancement with psychosocial intervention

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in Weiss Functional Impairment Rating Scale (WFIRS-P), parent rating
Tidsram: baseline, six months, 12 months; 16 months (control group)
The WFIRS-P is used for the assessment of psychosocial functioning of children diagnosed with ADHD.
baseline, six months, 12 months; 16 months (control group)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in Symptom Checklist for Attention Deficit/Hyperactivity Disorder (FBB-ADHS), parent rating
Tidsram: baseline, six months, 12 months; 16 months (control group)
The FBB-ADHS is used to assess symptoms of ADHD according to DSM-IV and ICD-10 rated by a parent.
baseline, six months, 12 months; 16 months (control group)
Change in Symptom Checklist for Oppositional Defiant and Conduct Disorder (FBB-SSV), parent rating
Tidsram: baseline, six months, 12 months; 16 months (control group)
The Symptom Checklist for Oppositional Defiant and Conduct Disorder (FBB-SSV) is used to assess symptoms of ODD and some of the symptoms of Conduct Disorders according to ICD-10 and DSM-IV.
baseline, six months, 12 months; 16 months (control group)
Change in Individual Problem Checklist (IPC), parent rating
Tidsram: baseline, six months, 12 months; 16 months
The IPC assesses individual problems as defined together with the parents. It represents the individual problems which were aimed to reduce with the treatment.
baseline, six months, 12 months; 16 months
Change in Satisfaction with Medication Scale (SAMS), parent rating
Tidsram: baseline, six months, 12 months; 16 months (control group)
The SAMS is used to assess parents' satisfaction with the medication of their child as well as with the effects of medication.
baseline, six months, 12 months; 16 months (control group)
Change in "Compliance Scale", parent rating
Tidsram: baseline, six months, 12 months; 16 months (control group)
Newly developed parent questionnaire consisting of five items to assess the medication compliance of the patient
baseline, six months, 12 months; 16 months (control group)
Questionnaire to assess adverse effects of medication, taken from the Day Profile of ADHD Symptoms (DAYAS)
Tidsram: baseline, six months, 12 months; 16 months (control group)
Subscale of the Day Profile of ADHD Symptoms (DAYAS) which assesses in 11 items the most frequent side effects of ADHD medication
baseline, six months, 12 months; 16 months (control group)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

University of Cologne

Samarbetspartners

Shire

Utredare

  • Huvudutredare: Manfred Doepfner, PhD, University of Cologne

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 maj 2012

Primärt slutförande (Förväntat)

1 december 2014

Avslutad studie (Förväntat)

1 mars 2015

Studieregistreringsdatum

Först inskickad

6 augusti 2012

Först inskickad som uppfyllde QC-kriterierna

7 augusti 2012

Första postat (Uppskatta)

8 augusti 2012

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

13 mars 2014

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

12 mars 2014

Senast verifierad

1 mars 2014

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • ADHD-TEAM-02
  • 2486738 (Annat bidrag/finansieringsnummer: Shire pharmaceutical development limited)

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på Attention Deficit-/Hyperactivity Disorder

Kliniska prövningar på Enhancement with psychosocial intervention

Sök liknande försök

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

CROs by country

CROs in Ukraine

Betingelser

Sällsynta sjukdomar

Läkemedelsinterventioner

Kosttillskott

Sponsor / medarbetare

Platser

3
Prenumerera